New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting

References

• Coates A, Abraham S, Kaye SB, et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203–208.
   PubMedGoogle Scholar
• de Boer-Dennert M, de Wit R, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997;76:1055–1061.
   PubMed Web of Science ®Google Scholar
• Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;7:189–195.
   PubMed Web of Science ®Google Scholar
• Dennis K, Zhang L, Lutz S, et al. International patterns of practice in the management of radiation therapy-induced nausea and vomiting. Int J Radiat Oncol Biol Phys. 2012;84:e49–e60.
   PubMed Web of Science ®Google Scholar
• Feyer PC, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer. 2011;19(Suppl 1):S5–S14.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Gralla RJ, du Bois A, et al. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer. 1998;6:221–227.
   PubMed Web of Science ®Google Scholar
• Morita M, Kuwano H, Ohno S, et al. Antiemetic effect of ramosetron during hyperthermo-chemo-radiotherapy for esophageal cancer. Anticancer Res. 2000;20:3631–3636.
   PubMed Web of Science ®Google Scholar
• Ruhlmann CH, Belli C, Dahl T, et al. Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study. Support Care Cancer. 2013;21:3425–3431.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi A, Usui H, Nishikimi K, et al. The efficacy of palonosetron plus dexamethasone in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study. Am J Clin Oncol. 2014. [Epub ahead of print].
   PubMedGoogle Scholar
• Emami H, Hematti S, Saeidian SM, et al. The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting. J Res Med Sci. 2015;20:329–333.
   PubMed Web of Science ®Google Scholar
• Jahn F, Riesner A, Jahn P, et al. Addition of the neurokinin-1-receptor antagonist (RA) aprepitant to a 5-hydroxytryptamine-RA and dexamethasone in the prophylaxis of nausea and vomiting due to radiation therapy with concomitant cisplatin. Int J Radiat Oncol Biol Phys. 2015;92:1101–1107.
   PubMed Web of Science ®Google Scholar
• Kawaguchi R, Tanase Y, Haruta S, et al. Addition of aprepitant to standard therapy for prevention of nausea and vomiting among patients with cervical cancer undergoing concurrent chemoradiotherapy. Int J Gynaecol Obstet. 2015;131:312–313.
   PubMed Web of Science ®Google Scholar
• Navari RM, Nagy CK, Le-Rademacher J, et al. Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol. 2016;14:141–147.
   PubMedGoogle Scholar
• Ruhlmann CH, Christensen TB, Dohn LH, et al. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol. 2016;17:509–518.
   PubMed Web of Science ®Google Scholar
• Kim K, Chie EK, Jang JY, et al. Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. Jpn J Clin Oncol. 2009;39:111–115.
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103–109.
   PubMed Web of Science ®Google Scholar
• Molassiotis A, Aapro M, Dicato M, et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage. 2014;47:839–848 e834.
   PubMed Web of Science ®Google Scholar
• Feyer P, Maranzano E, Molassiotis A, et al. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer. 2005;13:122–128.
   PubMed Web of Science ®Google Scholar
• Italian Group for Antiemetic Research. Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for antiemetic research in radiotherapy. Int J Radiat Oncol Biol Phys. 1999;44:619–625.
   PubMed Web of Science ®Google Scholar
• Maranzano E, De Angelis V, Pergolizzi S, et al. A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol. 2010;94:36–41.
   PubMed Web of Science ®Google Scholar
• MASCC/ESMO antiemetic guideline 2016 [cited 2016 Apr 10]. Available from: http://www.mascc.org/antiemetic-guidelines
   Google Scholar
• Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–4198.
   PubMed Web of Science ®Google Scholar
• Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–98.
   PubMed Web of Science ®Google Scholar
• Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–1161.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–1921.
   PubMed Web of Science ®Google Scholar
• Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–1598.
   PubMed Web of Science ®Google Scholar
• Rodel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:979–989.
   PubMed Web of Science ®Google Scholar
• Fraunholz I, Grau K, Weiss C, et al. Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy. Strahlenther Onkol. 2011;187:1–6.
   PubMed Web of Science ®Google Scholar
• Ruhlmann CH, Iversen TZ, Okera M, et al. Multinational study exploring patients’ perceptions of side-effects induced by chemo-radiotherapy. Radiother Oncol. 2015;117:333–337.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Brames MJ, Dreicer R, et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer. 2007;15:1293–1300.
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Summers Y, Jordan K, et al. Amisulpride, a dopamine D2/D3-antagonist, prevents chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic cisplatin or anthracycline-cyclophosphamide regimens: a randomised, double-blind, placebo-controlled, dose-ranging trial. 18th ECCO – 40th ESMO European Cancer Congress, 2015 Sept 25–29, Vienna; abstract 1573.
   Google Scholar
• Kocak-Uzel E, Gunn GB, Colen RR, et al. Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. Radiother Oncol. 2014;111:281–288.
   PubMed Web of Science ®Google Scholar